Table 1

Baseline demographic and clinical characteristics

BI 655064 (n=44)Placebo (n=23)
Age, years53.7±13.355.1±8.3
Female, n (%)37 (84.1)18 (78.3)
BMI26.06±4.5731.09±5.67
Region, n (%)
 Eastern Europe28 (63.6)15 (65.2)
 Western Europe16 (36.4)8 (34.8)
Ethnicity, n (%)
 White43 (97.7)23 (100)
 Asian1 (2.3)0
Disease duration, years8.3±7.55.8±4.7
Anti-TNFα naive, n (%)38 (86.4)23 (100)
DAS28-CRP5.39±0.855.53±0.79
DAS28-ESR6.21±0.736.16±0.80
CRP, mg/L9.80±12.6323.61±26.46
ESR, mm/hour37.45±18.6744.45±23.76
Duration of morning stiffness, mins84.1±61.667.3±53.1
SJC 6614.38±7.4112.86±6.94
TJC 6821.25±11.8719.77±10.84
  • Except where indicated otherwise, values are mean±SD.

  • BMI, body mass index; CRP, C-reactive protein;DAS28, Disease Activity Score in 28 joints;ESR, erythrocyte sedimentation rate; SD, standard deviation; SJS 66, swollen joint count based on 66 joints; TJC 68, tender joint count based on 68 joints; TNFα, tumour necrosis factor α.